The Foundation of Sarcoidosis Research (FSR) maintains a strong Scientific Advisory Board (SAB) composed of world renowned key opinion leaders within the fields of sarcoidosis, medical research, therapy development, and medical practice. The SAB helps advance FSR towards its mission dedicated to finding a cure for this disease and to improving care for sarcoidosis patients.

 

Daniel Culver, DO
FSR SAB Chair
Cleveland Clinic
Marc Judson, MD
Department of Medicine, MC-91
Albany Medical College
Robert Baughman, MD
University of Cincinnati
Craig Lipset
Head of Clinical Innovation
Pfizer
Edward Chen. MD
Johns Hopkins University
Lisa Maier, MD
National Jewish Health
Ulrich Costabel, MD, FERS
University of Duisburg-Essen
 Dave Moller, MD
Johns Hopkins University
Elliott Crouser, MD
Ohio State University
Adam Morgenthau, MD
Icahn School of Medicine at Mount Sinai
Seamas Donnelly, MD
Trinity College Dublin
Misha Rosenbach, MD
University of Pennsylvania
Wonder Drake, MD
Vanderbilt University
Milton Rossman, MD
University of Pennsylvania
Marjolein Drent, MD, PhD
St. Antonius Hospital
President of WASOG
Leslie Serchuck, MD
Children’s Hospital of Philadelphia
Andrew Fontenot, MD
University of Colorado
Barney Stern, MD
University of Maryland
Skip Garcia, MD
University of Arizona
Dominique Valeyre, MD
Hôpital Avicenne
W. Ennis James, MD
Medical University of South Carolina

Please note: While FSR receives guidance and input from our Scientific Advisory Board (SAB), it is not to be implied that all SAB members support or are in agreement in each specific FSR initiative or approach. As with most professional groups, members may have differing perspectives and opinions on various issues. FSR’s intent is always to work toward consensus with our experts as much as feasible while addressing patient and research needs.

Meet our staff.